Outlook Therapeutics, Inc. trades on the Nasdaq stock exchange under the ticker symbol OTLK as a clinical-stage biopharmaceutical enterprise. Investors buy and share its equity to gain financial exposure to ophthalmic drug development, with share valuations reacting dynamically to regulatory drug application milestones, clinical trial progress, and commercialization updates for its advanced retinal disease therapies.